However, the dramatic reduction of NFκB upon GTA treatment in colon tumor cells is highly relevant given the reduced levels of circulating GTAs in CRC patients [17,18] and the well-established inflammatory component of this disease [42]. This evidence concerns the gene NFKB1 and colorectal carcinoma.